Exhibit 23.1


                          Independent Auditors' Consent
                          -----------------------------

The Board of Directors and Shareholders
Antares Pharma, Inc.:

We consent to the incorporation by reference in the registration statement (Nos.
333-20389, 333-40483, 333-64480) on Form S-8 and registration statements (Nos.
333-61950, 333-96739) on Form S-3 of Antares Pharma, Inc. (formerly known as
Medi-Ject Corporation) of our report dated March 14, 2003, with respect to the
consolidated balance sheets of Antares Pharma, Inc. and subsidiaries as of
December 31, 2001 and 2002, and the related consolidated statements of
operations, shareholders' equity (deficit) and comprehensive loss, and cash
flows for each of the years in the three-year period ended December 31, 2002,
and the related financial statement schedule, which reports appear in the
December 31, 2002, annual report on Form 10-K of Antares Pharma, Inc.

The audit report on the consolidated financial statements of Antares Pharma,
Inc. and subsidiaries referred to above contains an explanatory paragraph that
states that the Company's negative working capital, recurring losses, and
negative cash flows from operations raise substantial doubt about the entity's
ability to continue as a going concern. The consolidated financial statements
and financial statement schedule included in the registration statement does not
include any adjustments that might result from the outcome of this uncertainty.

Our report on the 2002 consolidated financial statements refers to the Company's
adoption of the cumulative deferral method of revenue recognition for licensing
arrangements effective January 1, 2000 and the provisions of Statement of
Financial Accounting Standards No. 142, "Goodwill and Other Intangible Assets,"
on January 1, 2002.


                                       /s/ KPMG LLP

Minneapolis, Minnesota
March 21, 2003